(NASDAQ: NKTX) Nkarta's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Nkarta's earnings in 2026 is -$104,084,000.On average, 7 Wall Street analysts forecast NKTX's earnings for 2026 to be -$114,528,172, with the lowest NKTX earnings forecast at -$122,263,190, and the highest NKTX earnings forecast at -$99,557,169. On average, 7 Wall Street analysts forecast NKTX's earnings for 2027 to be -$121,621,576, with the lowest NKTX earnings forecast at -$148,113,122, and the highest NKTX earnings forecast at -$100,305,719.
In 2028, NKTX is forecast to generate -$112,710,265 in earnings, with the lowest earnings forecast at -$115,975,369 and the highest earnings forecast at -$108,539,771.